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„When the motor conked out, we paddled home.  
Boy was I glad I was wearing Rely.” 
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I will try to explain the safety aspects of 
beneficial microbes as straightforward as Albert 
Einstein did, when asked to comment on the new 
technology – the radio: 
 
- You see, wire telegraph is a kind of a very, 
very long cat. You pull his tail in New York 
and his head is meowing in Los Angeles. 
Do you understand this? And radio 
operates exactly the same way: you send 
signals here, they receive them there. The 
only difference is that there is no cat.  
— Albert Einstein 
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Current international definition: 
   „Probiotics are live microorganisms, which when 
administered in adequate amount confer a health 
benefit on the host.” 
        
  
      „Probiotyki to żywe drobnoustroje, które podane    
w odpowiedniej ilości wywierają korzystny 
wpływ na zdrowie gospodarza.” – Polish Society 
for Probiotics and Prebiotics 
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Adverse reactions: 
   According to FAO/WHO guidelines from 2001 
and 2006, probiotics may be (no longer) 
theoretically responsible for different types of 
adverse reactions: 
 
1. Systemic infections 
2. Deleterious metabolic effects 
3. Excessive immune stimulation in susceptible 
individuals 
4. Gene transfer 
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No man's life, liberty, or 
property are safe while the 
legislature is in 
session.  
— Mark Twain 
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Safety 
• Parameters, that should be taken into account when 
analyzing beneficial microbes’ safety are: 
 
- pathogenicity,  
- potential for causing infections,  
- virulence, including toxin production,  
- metabolic activity and  
- inherent characteristics of a given genus and species 
(and recently also the strain) of the microbe.  
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Safety (continued) 
    Summing up, the studies recommended by  
FAO/WHO regarding probiotic safety encompass:  
 
     
1. Determination of antibiotic resistance patterns 
 
2. Assessment of certain metabolic activities  
    (e.g., D-lactate production, bile salt deconjugation) 
 
3. Assessment of side-effects during human studies 
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4. If the strain under evaluation belongs to a species that 
is a known mammalian toxin producer, it must be 
tested for toxin production. One possible scheme for 
testing toxin production has been recommended by the 
EU Scientific Committee on Animal Nutrition (SCAN, 
2000) 
 
5. If the strain under evaluation belongs to a species with 
known hemolytic potential, determination of 
hemolytic activity is required 
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Safety (continued) 
6. Epidemiological surveillance of adverse incidents in 
consumers (post-market)      
  
    Furthermore, in the light of recent developments, and 
in agreement with ISAPP – evaluation showing no 
infectivity and no adverse events of the probiotic 
strain, performed on immunocompromised animal 
models, will increase the safety profile of the tested 
strain.       
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Safety (continued) 
Drug vs. Dietary Supplement or Food 
   In countries outside the USA, beneficial microbes and 
preparations containing such strains have various 
designations: 
- In some countries, incl. those in the EU, probiotics 
were registered as drugs previously and automatically 
stayed drugs when legislation changed.  
- In other countries beneficial microbes are contained in 
preparations which qualify as food supplements or 
food containing beneficial strains, e.g. dairy products.  
They are considered to have GRAS status. 
Health claims control = EFSA. 
Still, in some countries there is no legislature.       
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Get your facts first, 
then you can distort 
them as you please.  
— Mark Twain 
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Dutch PROPATRIA study 
(PRObiotics in PAncreatitis TRIAl) as a catalyst 
 
• Multicenter, randomized, double-blinded, placebo controlled 
clinical trial on 298 patients with severe acute pancreatitis. 
• Aim: to show less complications with multispecies probiotic 
preparation use 
• Composition: Ecologic 641 - Lactobacillus acidophilus, L. casei, 
L. salivarius, Lactococcus lactis, Bifidobacterium bifidum and B. 
lactis in a dose 1010 of bacteria.  
• Dosing: twice daily via nasojejunal tube for 28 days 
• Unexpected result: higher mortality in the probiotic group. 
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• Groups were similar as to the patient type, severity of 
symptoms and course of the disease.  
• Mortality upon completion of the study: 24 persons died 
in the probiotic group vs. 9 persons in the placebo 
group.  
• Nine patients in the probiotic group suffered from bowel 
ischemia (8 died), none in the placebo group (p=0.004).  
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PROPATRIA (continued) 
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There are three kinds of 
lies: lies, damned lies, 
and statistics.  
— Mark Twain 
ASM GM Ambassadors Forum, New Orleans, USA, May 20-24, 2011 
Case from the USA  (post transplant) 
  
• 56 year old HIV+ patient undergoing lung transplant. 
• Aim: prevention of C. difficile associated diarrhea 
• Standard regimen used in that institution was to administer 
Lactobacillus GG the day after the surgical procedure.  
• Unexpected result: A week post discharge from the hospital the 
patient was diagnosed with empyema and the same probiotic 
strain that was administered earlier on was isolated from the 
sample. The patient had to undergo decortication (removal of 
pleura) because of relapsing empyema and was given a two week 
IV ampicillin with sulbactam. Patient’s status is currently 
satisfactory. 
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Case from Poland (cardiosurgical) 
  
• 24 year old female patient after aortic valve replacement. 
• Cel: supplementary probiotic rx with perioperative antimicrobial 
prophylaxis 
• Lactobacillus rhamnosus Pen, E/N, Oxy before and after surgery.  
• Unexpected result: Sepsis. Molecular confirmation that the 
isolated strains were the same as the probiotic ones used. 
Antimicrobial treatment was successful. 
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German study in the prevention of atopic dermatitis 
  
• Randomized, double-blinded, placebo controlled clinical study on 
94 patients. 
• Aim: primary prevention of atopic dermatits by administering a 
probiotic 
• Lactobacillus GG (ATCC 53103) 5x109 CFU 2 x daily per os.  
• Unexpected result: supplementation of pregnant women and 
newborns did not lower the number of cases and had no influence 
on the course of atopic dermatitis. Unfortunately it was also 
associated with relapsing episodes of wheezing. The German 
team does not recommend the use of Lactobacillus GG for the 
prevention of atopic dermatitis. 
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Australian study on atopic dermatitis 
  
• Randomized, double-blinded, placebo controlled on 178 patients. 
• Aim: lower the incidence risk of atopic dermatitis by 
administering a probiotic 
• Lactobacillus acidophilus LAVRI-A1 3x109 daily per os. 
• Unexpected result: probiotic supplementation in the first 6 
months of life not only did not lower the incidence of atopic 
dermatitis but even increased the likelihood of allergic disorders 
in the studied group.  
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Review study of Lactobacillus infections:          
over 200 cases analyzed 
  
• Retrospective. 
• Aim: evaluation of cases, treatment and its efficacy 
• Lactobacillus was most often isolated in endocarditis, 
bacteriemia, peritonitis, abscesses and meningitis cases. 
• Results: isolates were shown to be most sensitive to erythromycin 
and clindamycin, and most resistant to vancomycin. The strain 
most sensitive to vanco: L. acidophilus. 
 Mortality ~30%, most often due to inapropriate rx and mixed 
infections.  
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 Postulated mechanisms of  
severe adverse events (SAE)  
related to probiotic use 
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1. Intestinal hypoxia, e.g.: 
 
(a) administration of 10 billion probiotic bacteria daily, 
including nasojejunal feeding, could have put additional 
local oxygen demand, worsening the already hypoxic 
state of the G.I. tract. 
  
(b) excessive number of (probiotic) bacteria, resulting in a 
local inflammatory state on the mucosal level. 
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 Postulated mechanisms of  






2. Microaspiration of G.I. tract flora. 
 
3. Damage to the intestinal barrier (mentioned in point no. 
1), including toxic action of drugs on the mucosa, 
leading to bacterial translocation. 
 
4. Ineffective treatment when using ”salvage 
antimicrobials”, owing to resistance of many probiotic 
strains. 
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Analyzing the current literature one may come to 
a conclusion that probiotic use may be 
riskyrisky even dangerous for the following: 
- persons severely immunocompromised, 
- persons with organ failure, 
- persons with severe chronic conditions,  
- persons undergoing complex surgical 
procedures.   
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RISK GROUPS FOR PROBIOTIC USE 
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• PLEASE NOTE! Statistics and generalizations are 
deceitful (papers on probiotics very often talk of 
”probiotics being safe owing to their long history of 
use by many millions of people…”). 
 
• Good example are airlines: millions of passengers 
travel by plane every year, it’s considered to be one of 
the safest means to travel, but disasters do happen.  
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If my neighbour beats his 
wife everyday, and I never 
do, then in the light of 
statistics we both beat our 
women every second day.  
— George Bernard Shaw 
 
 
ASM GM Ambassadors Forum, New Orleans, USA, May 20-24, 2011 
• People love sensational news. 
 
• That is the reason why adverse events related to 
probiotics receive so much more publicity than 
their beneficial effects. 
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CONCLUSION 2 
ASM GM Ambassadors Forum, New Orleans, USA, May 20-24, 2011 
31 
A scientist is a mimosa 
when he himself has made 
a mistake, and a roaring 
lion when he discovers a 
mistake of others.  
— Albert Einstein 
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• Current situation regarding probiotics and adverse 
events is plain ignorance. It’s similar to hospital 
infections 20 years ago in communist Poland – if 
you’d ask a physician back then he would tell you 
there is no such thing as a hospital infection!  
• The time has come to realise that probiotics like any 
drugs, medicinal products or supplements may be 
responsible for adverse events, also SAE, in selected 
groups of people. Maybe it’s also time for the 
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Errors are a path to the 
truth.  
— Fyodor Dostoyevsky  
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There is no bad tobacco,           
as there are no ugly 
women.  
— Albert Einstein 
 
There are no bad 
probiotics, as there are no 
ugly women. 
— Piotr Kochan 




New definition of probiotics should be proposed: 
  
     
 „Probiotics are live microorganisms, which when 
administered in adequate amount confer a health 
benefit on the host but should be avoided in certain 
risk groups.” 
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Science becomes 
dangerous only when it 
imagines that it has 
reached its goal.  
— George Bernard Shaw 
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